Please wait a minute...
J Zhejiang Univ (Med Sci)  2020, Vol. 49 Issue (4): 419-424    DOI: 10.3785/j.issn.1008-9292.2020.08.17
    
Advances in treatment of narcolepsy
XU Qinglin1,2(),LOU Guodong3,WANG Tiantian3,ZHANG Lisan1,2,*()
1. Department of Neurology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China
2. Center for Sleep Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China
3. Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China
Download: HTML( 11 )   PDF(1066KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Narcolepsy is the most common cause of excessive daytime sleepiness (EDS) following obstructive sleep apnea. Its treatment aims to reduce EDS and cataplexy, improve nighttime sleep disturbance, sleep paralysis and sleep-related hallucinations. Pitolisant (a histamine H3 receptor antagonist) and solriamfetol (a norepinephrine reuptake inhibitor) have recently been approved effective for narcolepsy in the United States and the European Union. Pitolisant has proved to be effective for both EDS and cataplexy. Besides being effective on EDS, solriamfetol seems to have advantages in abuse potential and withdrawal syndrome. As potential treatments for EDS and cataplexy associated with narcolepsy, several new drugs are being developed and tested. These new drugs include new hydroxybutyrate preparations (controlled release sodium hydroxybutyrate FT218, low sodium hydroxybutyrate JZP-258), selective norepinephrine reuptake inhibitor (AXS-12), and modafinil combined with astroglial junction protein inhibitor (THN102). This paper reviews the recently approved drugs and potential treatments for narcolepsy.



Key wordsNarcolepsy      Pitolisant      Solriamfetol      Sodium oxybate      Preparation      Side effect      Review     
Received: 30 June 2020      Published: 27 September 2020
CLC:  R741  
  R969.4  
Corresponding Authors: ZHANG Lisan     E-mail: rainkei@zju.edu.cn;zls09@zju.edu.cn
Cite this article:

XU Qinglin,LOU Guodong,WANG Tiantian,ZHANG Lisan. Advances in treatment of narcolepsy. J Zhejiang Univ (Med Sci), 2020, 49(4): 419-424.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2020.08.17     OR     http://www.zjujournals.com/med/Y2020/V49/I4/419


发作性睡病的药物治疗进展

发作性睡病是致残性白天睡眠增多的最常见原因之一,其治疗旨在减少白天睡眠增多和猝倒,改善夜间睡眠紊乱、睡眠瘫痪及与睡眠有关的幻觉。2019年,组胺H3受体拮抗剂替洛利生(Pitolisant)和多巴胺及去甲肾上腺素再摄取抑制剂索利氨酯(Solriamfetol)分别在欧盟和美国上市,前者具有促醒和抗猝倒作用,后者也有促醒作用,且戒断症状和滥用的发生率更低。目前,控释型羟丁酸钠(FT218)、低钠型羟丁酸盐(JZP-258)、选择性去甲肾上腺素再摄取抑制剂(瑞波西汀,又称AXS-12)以及莫达非尼联合氟卡尼制剂(THN102)等药物仍在开发和测试中,均可作为治疗发作性睡病相关白天睡眠增多和猝倒的潜在药物。本文重点介绍这些最近研发的发作性睡病治疗药物。


关键词: 发作性睡病,  替洛利生,  索利氨酯,  羟丁酸钠,  制剂,  副作用,  综述 
[1]   BASSETTI C , ADAMANTIDIS A , BURDAKOV D et al. Narcolepsy-clinical spectrum, aetiopathophysiology, diagnosis and treatment[J]. Nat Rev Neurol, 2019, 15 (9): 519- 539
doi: 10.1038/s41582-019-0226-9
[2]   HUBLIN C , PARTINEN M , KAPRIO J et al. Epidemiology of narcolepsy[J]. Sleep, 1994, 17 (8 Suppl): S7- 12
doi: 10.1093/sleep/17.suppl_8.s7
[3]   HEIER M S , EVSIUKOVA T , WILSON J et al. Prevalence of narcolepsy with cataplexy in Norway[J]. Acta Neurol Scand, 2009, 120 (4): 276- 280
doi: 10.1111/j.1600-0404.2009.01166.x
[4]   TIÓ E, GAIG C, GINER-SORIANO M, et al. The prevalence of narcolepsy in Catalunya (Spain)[J/OL]. J Sleep Res, 2018, 27(5): e12640. DOI: 10.1111/jsr.12640.
[5]   中华医学会神经病学分会, 中华医学会神经病学分会睡眠障碍学组, 解放军医学科学技术委员会神经内科专业委员会睡眠障碍学组 . 中国发作性睡病诊断与治疗指南[J]. 中华神经科杂志, 2015, 48 (6): 445- 452
Chinese Society of Neurology , Sleep Disorders Group of Chinese Society of Neurology , Sleep Disorders Group of Neurology Commission of Military Medical-Scientific Commission . Chinses guideline for narcolepsy diagnosis and treatment[J]. Chinese Journal of Neurology, 2015, 48 (6): 445- 452
doi: 10.3760/cma.j.issn.1006-7876.2015.06.003
[6]   BLACK J , REAVEN N L , FUNK S E et al. Medical comorbidity in narcolepsy:findings from the Burden of Narcolepsy Disease (BOND) study[J]. Sleep Med, 2017, 33 13- 18
doi: 10.1016/j.sleep.2016.04.004
[7]   BLACK J , REAVEN N L , FUNK S E et al. The Burden of Narcolepsy Disease (BOND) study:health-care utilization and cost findings[J]. Sleep Med, 2014, 15 (5): 522- 529
doi: 10.1016/j.sleep.2014.02.001
[8]   SCHNEIDER L , MIGNOT E . Diagnosis and management of narcolepsy[J]. Semin Neurol, 2017, 37 (4): 446- 460
doi: 10.1055/s-0037-1605554
[9]   SATEIA M J . International Classification of sleep disorders-third edition[J]. Chest, 2014, 146 (5): 1387- 1394
doi: 10.1378/chest.14-0970
[10]   BROUGHTON R J , FLEMING J A , GEORGE C F et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy[J]. Neurology, 1997, 49 (2): 444- 451
doi: 10.1212/wnl.49.2.444
[11]   MIGNOT E J . A practical guide to the therapy of narcolepsy and hypersomnia syndromes[J]. Neurotherapeutics, 2012, 9 (4): 739- 752
doi: 10.1007/s13311-012-0150-9
[12]   ARAN A , EINEN M , LIN L et al. Clinical and therapeutic aspects of childhood narcolepsy-cataplexy:a retrospective study of 51 children[J]. Sleep, 2010, 33 (11): 1457- 1464
doi: 10.1093/sleep/33.11.1457
[13]   GUILLEMINAULT C , RAYNAL D , TAKAHASHI S et al. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride[J]. Acta Neurol Scand, 1976, 54 (1): 71- 87
doi: 10.1111/j.1600-0404.1976.tb07621.x
[14]   JIN L , SHI L , ZHANG Y et al. Antidepressants for the treatment of narcolepsy:A prospective study of 148 patients in northern China[J]. J Clin Neurosci, 2019, 63 27- 31
doi: 10.1016/j.jocn.2019.02.014
[15]   MAYER G , PLAZZI G , IRANZO á et al. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1:a postauthorization, noninterventional surveillance study[J]. Sleep, 2018, 41 (9):
doi: 10.1093/sleep/zsy128
[16]   DAUVILLIERS Y , BASSETTI C , LAMMERS G J et al. Pitolisant versus placebo or modafinil in patients with narcolepsy:a double-blind, randomised trial[J]. Lancet Neurol, 2013, 12 (11): 1068- 1075
doi: 10.1016/S1474-4422(13)70225-4
[17]   KOLLB-SIELECKA M , DEMOLIS P , EMMERICH J et al. The European Medicines Agency review of pitolisant for treatment of narcolepsy:summary of the scientific assessment by the Committee for Medicinal Products for Human Use[J]. Sleep Med, 2017, 33 125- 129
doi: 10.1016/j.sleep.2017.01.002
[18]   SZAKACS Z , DAUVILLIERS Y , MIKHAYLOV V et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy:a randomised, double-blind, placebo-controlled trial[J]. Lancet Neurol, 2017, 16 (3): 200- 207
doi: 10.1016/S1474-4422(16)30333-7
[19]   DAUVILLIERS Y , ARNULF I , SZAKACS Z et al. Long-term use of pitolisant to treat patients with narcolepsy:Harmony Ⅲ Study[J]. Sleep, 2019, 42 (11):
doi: 10.1093/sleep/zsz174
[20]   THORPY M J . Recently approved and upcoming treatments for narcolepsy[J]. CNS Drugs, 2020, 34 (1): 9- 27
doi: 10.1007/s40263-019-00689-1
[21]   THORPY M J , SHAPIRO C , MAYER G et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy[J]. Ann Neurol, 2019, 85 (3): 359- 370
doi: 10.1002/ana.25423
[22]   MALHOTRA A , SHAPIRO C , PEPIN J L et al. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea[J]. Sleep, 2020, 43 (2):
doi: 10.1093/sleep/zsz220
[23]   ABAD V C , GUILLEMINAULT C . New developments in the management of narcolepsy[J]. Nat Sci Sleep, 2017, 9 39- 57
doi: 10.2147/NSS.S103467
[24]   BARKER E C , FLYGARE J , PARUTHI S et al. Living with narcolepsy:current management strategies, future prospects, and overlooked real-life concerns[J]. Nat Sci Sleep, 2020, 12 453- 466
doi: 10.2147/NSS.S162762
[25]   BOGAN R, THORPY M, DAUVILLIERS Y, et al. Efficacy and safety of JZP-258 in a phase 3 double-blind, placebo-controlled, randomised-withdrawl study in adults with narcolepsy with cataplexy[R]. Vancouver: Biennial World Sleep Congress, 2019.
[26]   HAJóS M , FLEISHAKER J C , FILIPIAK-REISNER J K et al. The selective norepinephrine reuptake inhibitor antidepressant reboxetine:pharmacological and clinical profile[J]. CNS Drug Rev, 2004, 10 (1): 23- 44
doi: 10.1111/j.1527-3458.2004.tb00002.x
[27]   SCHMIDT C , LEIBIGER J , FENDT M . The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram[J]. Behav Brain Res, 2016, 308 205- 210
doi: 10.1016/j.bbr.2016.04.033
[28]   LARROSA O , DE LA LLAVE Y , BARIO S et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy:a pilot study[J]. Sleep, 2001, 24 (3): 282- 285
doi: 10.1093/sleep/24.3.282
[29]   FDA Grants Axsome Therapeutics' AXS-12 Breakthrough Therapy Designation for Treatment of Narcolepsy[N/OL]. (2020-08-05)[2020-08-10]. https://www.spjnews.com/2020/08/05/fda-grants-axsome-therapeutics-axs-12-breakthrough-therapy-designation-for-treatment-of-narcolepsy/.
[30]   BOIVIN D B , MONTPLAISIR J , PETIT D et al. Effects of modafinil on symptomatology of human narcolepsy[J]. Clin Neuropharmacol, 1993, 16 (1): 46- 53
doi: 10.1097/00002826-199302000-00005
[31]   DUCHêNE A , PERIER M , ZHAO Y et al. Impact of astroglial connexins on modafinil pharmacological properties[J]. Sleep, 2016, 39 (6): 1283- 1292
doi: 10.5665/sleep.5854
[32]   National Institutes of Health. Safety and efficacy of THN102 on sleepiness in narcoleptic patients[EB/OL]. (2016-07-01)[2019-04-26]. https://clinicaltrials.gov/ct2/show/NCT02821715.
[33]   BONVALET M , OLLILA H M , AMBATI A et al. Autoimmunity in narcolepsy[J]. Curr Opin Pulm Med, 2017, 23 (6): 522- 529
doi: 10.1097/MCP.0000000000000426
[34]   YUKITAKE H , FUJIMOTO T , ISHIKAWA T et al. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice[J]. Pharmacol Biochem Behav, 2019, 187 172794
doi: 10.1016/j.pbb.2019.172794
[1] JIANG Peiran, WANG Zhiping. Progress on axon regeneration in model organisms[J]. J Zhejiang Univ (Med Sci), 2020, 49(4): 500-507.
[2] CHEN Junyi,YANG Xiang,FANG Xuexian,WANG Fudi,MIN Junxia. The role of ferroptosis in chronic diseases[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 44-57.
[3] ZHAO Weixia,ZOU Wei. Intrinsic and extrinsic mechanisms regulating neuronal dendrite morphogenesis[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 90-99.
[4] WANG Yi,LU Yunbi. Poly adenosine diphosphate-ribosylation and neurodegenerative diseases[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 100-106.
[5] YU Qing, XIONG Xiufang, SUN Yi. Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 1-19.
[6] DUAN Lingyan,YIN Xiangju,MENG Hong'en,FANG Xuexian,MIN Junxia,WANG Fudi. Progress on epigenetic regulation of iron homeostasis[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 58-70.
[7] LI Ai,ZHANG Tianyuan,GAO Jianqing. Progress on utilizing mesenchymal stem cells as cellular delivery system for targeting delivery of as drug/gene for anti-tumor therapy[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 20-34.
[8] HUANG Yaoping,YANG Feng,ZHOU Tianhua,XIE Shanshan. Emerging roles of Hippo signaling pathway in gastrointestinal cancers and its molecular mechanisms[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 35-43.
[9] ZHONG Wen,LOU Yan,QIU Chenyang,LI Donglin,ZHANG Hongkun. Antithrombotic therapy after iliac vein stenting[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 131-136.
[10] XU Yiming,YING Kejing. Research progress on neutrophil extracellular traps in tumor[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 107-112.
[11] LIU Xiaoxiao,GUO Liqiong,LIANG Cheng. Research progress on electroencephalogram characteristics of anti-N-methyl-D-aspartate receptor encephalitis[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 118-123.
[12] FANG Juan,PAN Zhicheng,GUO Xiaogang. Research advance of ANRIL on atherosclerosis by regulating cell proliferation and apoptosis[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 113-117.
[13] WANG Shiying,GU Xinhua. Progress on clinical application of orthodontic-implant combined therapy[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 124-130.
[14] WANG Yifeng, WANG Zhiping. Research progress on intrinsic signaling pathways in axon regeneration[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 82-89.
[15] DING Yidan,LI Wenbin,WANG Rong,ZHANG Jianchun. Research progress on the effects of plateau hypoxia on blood-brain barrier structure and drug permeability[J]. J Zhejiang Univ (Med Sci), 2019, 48(6): 668-673.